ID: ALA4160428

Max Phase: Preclinical

Molecular Formula: C15H19BrN2O4

Molecular Weight: 371.23

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(/C=C/c1cccc(Br)c1)NC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O

Standard InChI:  InChI=1S/C15H19BrN2O4/c16-10-3-1-2-9(6-10)4-5-13(20)18-7-11-14(21)15(22)12(19)8-17-11/h1-6,11-12,14-15,17,19,21-22H,7-8H2,(H,18,20)/b5-4+/t11-,12+,14+,15-/m1/s1

Standard InChI Key:  RTHXIZRJYAXMGL-MOJYZWANSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 371.23

Molecular Weight (Monoisotopic): 370.0528

AlogP: -0.37

#Rotatable Bonds: 4

Polar Surface Area: 101.82

Molecular Species: NEUTRAL

HBA: 5

HBD: 5

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.92

CX Basic pKa: 7.85

CX LogP: -0.05

CX LogD: -0.63

Aromatic Rings: 1

Heavy Atoms: 22

QED Weighted: 0.47

Np Likeness Score: 0.54

References

1. Li HY, Lee JD, Chen CW, Sun YC, Cheng WC..  (2018)  Synthesis of (3S,4S,5S)-trihydroxylpiperidine derivatives as enzyme stabilizers to improve therapeutic enzyme activity in Fabry patient cell lines.,  144  [PMID:29289886] [10.1016/j.ejmech.2017.12.036]

Source

Source(1):

• Scientific Literature